Burjeel Holdings has inaugurated the Thalassemia & Sickle Cell Center at Burjeel Medical City in Abu Dhabi, UAE, enhancing care for individuals with inherited blood disorders.
The centre is set to provide a patient-centric approach to treatment, supported by a multidisciplinary team of specialists. It operates seven days a week, featuring a dedicated transfusion unit and fully integrated outpatient services.
Go deeper with GlobalData
It is positioned with extended transfusion services in the UAE through Burjeel’s hospital network, globally validated iron overload MRI quantification in the liver and heart, and in-house molecular genotyping capabilities.
Experts at the Thalassemia & Sickle Cell Center can manage both paediatric and adult cases, addressing the high prevalence rates of these diseases in the region.
Situated within a quaternary care facility, the centre ensures various medical and surgical subspecialties are directly accessible.
This facilitates seamless referrals and management of complications associated with thalassemia and sickle cell disease.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBurjeel Holdings group chief research officer and Thalassemia & Sickle Cell Center director Khaled Musallam said: “What makes this centre unique is the combination of global clinical expertise, access to the latest therapies, and the ability to deliver care in line with international guidelines authored by the very people leading the services here.”
The centre’s care range spans from diagnosis through adulthood, with tailored transition programmes and treatments for various thalassemia conditions and sickle cell disease.
It adheres to global standards, encompassing those of the Thalassaemia International Federation, with adaptations for the local population.
Furthermore, the centre will collaborate with the Center for Research on Rare Blood Disorders at Burjeel Medical City, spearheaded by Khaled Musallam, to enrol patients in global clinical trials.
This partnership will provide access to the latest treatment innovations, encompassing disease-modifying and curative therapies.
Last month, Burjeel Holdings collaborated with US-based company Paige to deploy FDA-approved AI in cancer diagnostics across the MENA region.
